---
sidebar_position: 62
---
           <p class="stitle-article-norm">Informed consent</p>
   <p class="norm">1.&nbsp;&nbsp;Informed consent shall be written, 
dated and signed by the person performing the interview referred to in 
point&nbsp;(c) of paragraph&nbsp;2, and by the subject or, where the 
subject is not able to give informed consent, his or her legally 
designated representative after having been duly informed in accordance 
with paragraph&nbsp;2. Where the subject is unable to write, consent may
 be given and recorded through appropriate alternative means in the 
presence of at least one impartial witness. In that case, the witness 
shall sign and date the informed consent document. The subject or, where
 the subject is not able to give informed consent, his or her legally 
designated representative shall be provided with a copy of the document 
or the record, as appropriate, by which informed consent has been given.
 The informed consent shall be documented. Adequate time shall be given 
for the subject or his or her legally designated representative to 
consider his or her decision to participate in the clinical 
investigation.</p>
   <p class="norm">2.&nbsp;&nbsp;Information given to the subject or, 
where the subject is not able to give informed consent, his or her 
legally designated representative for the purposes of obtaining his or 
her informed consent shall:</p>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(a)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">enable the subject or his or her legally designated representative to understand:</p>
         <div class="grid-container grid-list">
            <div class="list grid-list-column-1">
               <span>(i)&nbsp;</span>
            </div>
            <div class="grid-list-column-2">
               <p class="norm">the nature, objectives, benefits, implications, risks and inconveniences of the clinical investigations;</p>
            </div>
         </div>
         <div class="grid-container grid-list">
            <div class="list grid-list-column-1">
               <span>(ii)&nbsp;</span>
            </div>
            <div class="grid-list-column-2">
               <p class="norm">the subject's rights and guarantees 
regarding his or her protection, in particular his or her right to 
refuse to participate in and the right to withdraw from the clinical 
investigation at any time without any resulting detriment and without 
having to provide any justification;</p>
            </div>
         </div>
         <div class="grid-container grid-list">
            <div class="list grid-list-column-1">
               <span>(iii)&nbsp;</span>
            </div>
            <div class="grid-list-column-2">
               <p class="norm">the conditions under which the clinical 
investigations is to be conducted, including the expected duration of 
the subject's participation in the clinical investigation; and</p>
            </div>
         </div>
         <div class="grid-container grid-list">
            <div class="list grid-list-column-1">
               <span>(iv)&nbsp;</span>
            </div>
            <div class="grid-list-column-2">
               <p class="norm">the possible treatment alternatives, 
including the follow-up measures if the participation of the subject in 
the clinical investigation is discontinued;</p>
            </div>
         </div>
      </div>
   </div>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(b)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">be kept comprehensive, concise, clear, 
relevant, and understandable to the subject or his or her legally 
designated representative;</p>
      </div>
   </div>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(c)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">be provided in a prior interview with a member of the investigating team who is appropriately qualified under national law;</p>
      </div>
   </div>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(d)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">include information about the applicable damage compensation system referred to in <a href='../CHAPTER VI/Article 69 - Damage compensation'> Article 69</a>; and</p>
      </div>
   </div>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(e)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">include the Union-wide unique single 
identification number of the clinical investigation referred to in 
<a href='../CHAPTER VI/Article 70 - Application for clinical investigations'> Article 70</a>(1) and information about the availability of the 
clinical investigation results in accordance with paragraph&nbsp;6 of 
this Article.</p>
      </div>
   </div>
   <p class="norm">3.&nbsp;&nbsp;The information referred to in 
paragraph&nbsp;2 shall be prepared in writing and be available to the 
subject or, where the subject is not able to give informed consent, his 
or her legally designated representative.</p>
   <p class="norm">4.&nbsp;&nbsp;In the interview referred to in 
point&nbsp;(c) of paragraph&nbsp;2, special attention shall be paid to 
the information needs of specific patient populations and of individual 
subjects, as well as to the methods used to give the information.</p>
   <p class="norm">5.&nbsp;&nbsp;In the interview referred to in 
point&nbsp;(c) of paragraph&nbsp;2, it shall be verified that the 
subject has understood the information.</p>
   <p class="norm">6.&nbsp;&nbsp;The subject shall be informed that a 
clinical investigation report and a summary presented in terms 
understandable to the intended user will be made available pursuant to 
<a href='../CHAPTER VI/Article 77 - Information from the sponsor at the end of a clinical investigation or in the event of a temporary halt or early termination'> Article 77</a>(5) in the electronic system on clinical investigations 
referred to in <a href='../CHAPTER VI/Article 73 - Electronic system on clinical investigations'> Article 73</a> irrespective of the outcome of the 
clinical investigation, and shall be informed, to the extent possible, 
when they have become available.</p>
   <p class="norm">7.&nbsp;&nbsp;This Regulation is without prejudice to
 national law requiring that, in addition to the informed consent given 
by the legally designated representative, a minor who is capable of 
forming an opinion and assessing the information given to him or her, 
shall also assent in order to participate in a clinical investigation.</p>